bluuebunny/crossref_metadata_2025_split huggingface dataset:
Platelet Release Reaction and Prostaglandin Pathway Activation in Angina Patients during Exercise: Effect of Indobufen
Authors: Pogliani E M , Fantasia R , Savino R , Montani M 
Published: January 2017

Platelet 14C-serotonin release induced by collagen, and platelet malondialdehyde (M.D.A.) generation induced by thrombin were assessed in twenty patients with stable angina, before and after exercise with a bicycle ergometer. The patients received a single oral 200 mg dose of indobufen or placebo according to a crossover design in double-blind conditions. The M.D.A. concentration increased when exercise was carried out after placebo, whereas indobufen markedly inhibited M.D.A. production and 14C-serotonin release. These results suggest that effort may be an important factor in activation of the platelet prostaglandin pathway and that the use of antithrombotic drugs may be appropriate in patients with angina.
Antiaggregant Effect of Indobufen (K3920) Measured by the Platelet Aggregate Filtration Pressure Test (PAFP)
Authors: Visonà A , Davanzo S , Bruno R , Pagnan A 
Published: January 2017

The platelet aggregate filtration pressure test (PAFP) was used to study the aggregant activity of single doses of 200 mg indobufen, administered either orally or by i.v. injection. This double-blind study using placebo in a crossover design was conducted in twelve patients whose baseline aggregation values were high. The compound showed markedly different antiaggregant activity from placebo at the various observation times after administration. The two administration routes did not produce any significant differences. The PAFP test can be useful in identifying atherosclerotic patients with platelet hyperaggregation, and for clinical pharmacology studies with platelet antiaggregant drugs.
Three-Day Clotrimazole Therapy for Vulvo-Vaginal Mycosis
Authors: Higashide Kohji , Kawaguchi Choji , Tomoda Yutaka 
Published: January 2017

A self-medication therapy with clotrimazole vaginal tablets, application of two tablets at bedtime on 3 consecutive days, was carried out to find out whether vulvo-vaginal mycoses can be treated more effectively and with fewer drop-outs when treatment is simpler and shorter. Our study included forty-one patients, seventeen of whom were in their second or third trimester of pregnancy. There was no significant difference between the efficacy rates in the pregnant (82·4%) and non-pregnant (83·3%) women. In 36 infections caused by various Candida species the cure rate was 91·7%; in 8 infections due to Torulopsis glabrata it was 75%. For thirty-three women with primary infections the cure rate was 84·8% and for eight women with recurrent infections it was 75%. The cure rate for the entire group of patients was 82·9% (thirty-four out of forty-one cases). Failures were seen in six out of thirty cases, i.e. in 16·7%. In one case burning was experienced after the insertion of the vaginal tablet so that treatment was discontinued.
Acute Gonococcal Urethritis: Treatment with a Single Dose of Rifampicin
Authors: Belli Luis , Ambrona Mario S , Gennaro Emilio A , Isola Enrique H , Rescigno Gilberte R González 
Published: January 2017

A total of 103 patients with acute gonococcal urethritis were treated with a single 1,200 mg dose of rifampicin. A 91·3% cure rate was obtained, as proved by the negative bacteriological controls effected on the 7th and 14th days after the initiation of therapy. Three pharyngeal infections and one ano-rectal infection responded successfully to the treatment. No signs of drug intolerance were detected with the stated dose. Reactivity to the VDRL test was not impaired during the duration of the study and three reactive cases were discovered. In previous studies of gonorrhoea we had observed a significant discrepancy between urine cultures and the urethral smears and, in view of this, it was decided to adopt the latter alone as a routine procedure. The proposed dose does not originate resistance to rifampicin in either the Hansen or Koch bacilli.
Nimesulide in the Short-Term Treatment of Inflammatory Process of Dental Tissues: A Double-Blind Controlled Trial against Oxyphenbutazone
Authors: Pais José Manuel , Rosteiro Filomena Maria 
Published: January 2017

One hundred out-patients with inflammatory process of dental tissues due to tooth extraction, root abscess alveolitis and periodontitis, were randomly assigned, according to a double-blind design, to one of two treatment groups with nimesulide (200 mg/day) or oxyphenbutazone (400 mg/day). By means of a seff-rating record, each patient rated his pain, difficulty of chewing, redness and swelling before starting, during and at the end of treatment. Nimesulide and oxyphenbutazone were both well tolerated and effective, but the improvements during the first and the second day of treatment were of greater magnitude in the nimesulide-treated patients. Nimesulide, being well tolerated, rapid acting and effective, could be considered as a drug of choice for the treatment of inflammatory process of dental tissues.
Our Experience with the Use of Buflomedil Chlorhydrate in a Mixed Population of Vasculopathic Patients
Authors: Battaglia L , Valgiusti D , Di Paola F M 
Published: January 2017

In the Observation Department of S. Giacomo Hospital the authors carried out a study on 242 patients, in whom they found a latent vascular pathology in some cases and a manifest vascular pathology in other cases. The patients were divided into two groups: patients at risk manifestly vasculopathic patients and they were then subdivided according to the compromised region. The subjects underwent sero-haematological and radiological tests, instrumental tests not involving operations such as Doppler ultrasonography and rheography, and tests involving operations such as angiography. Both medical and surgical therapeutic means were used. Then the authors carried out a therapeutic trial with buflomedil chlorhydrate on subjects with obliterative vasculopathy with different aetiologies.
Treatment of Essential Hypertension with Beta-Blocker plus Diuretic: A Study of 1402 Patients Treated by General Practitioners with Acebutolol 200 mg Combined with Hydrochlorothiazide 12·5 mg (‘Secadrex’) Once Daily for 3 Months
Authors: McGowan G K , Baker P G 
Published: January 2017

One thousand four hundred and two patients with essential hypertension were treated by their general practitioners for 3 months with one tablet daily consisting of 200 mg acebutolol plus 12·5 mg hydrochlorothiazide: 813 were newly diagnosed and 589 were known hypertensives already on treatment. There was no ‘wash-out’ period before the latter changed to the study treatment. Newly diagnosed hypertensives had an average initial mean arterial pressure (MAP) of 129·9 mm Hg which fell on average by 18·2% during the study: 79% of patients had good results with final MAP levels less than 113 mm Hg (equivalent to e.g., 160/90 mm Hg), and a further 7% also had good results in that MAP fell more than 15%, another 12·5% had moderate results (falls of 5% to 15%): and only 1·5% had poor results (fell less than 5%). Known hypertensives had an average MAP of 127 mm Hg on previous treatment, which fell on average by 15·4% during this study: 70% of patients had good results with final MAP levels less than 113 mm Hg and a further 7% also had good results in that MAP fell more than 15%: 18% had moderate results and 3% poor results. Pulse rate fell by 12·5% in newly diagnosed and 10% in known treated hypertensives. If allowance is made for withdrawals due to side-effects and to the need for more than one tablet of Secadrex daily, then over all 75·7% had a good blood pressure response to study medication, 13·7% a moderate response and 10·7% a poor response. Adverse effects caused the withdrawal of 4% of newly diagnosed and 5% of treated hypertensives, predominantly nausea/vomiting, lassitude/fatigue and malaise. Adverse symptoms not causing withdrawal occurred in newly diagnosed patients with a frequency of 17·1 per 100 patients prior to the study when untreated and 14·1 during the study: in treated hypertensives the figures were 53·1 per 100 patients on previous treatment and 18·2 during the study.
Efficacy of Iron Therapy: A Comparative Evaluation of Four Iron Preparations Administered to Anaemic Pregnant Women
Authors: Fochi F , Ciampini M , Ceccarelli G 
Published: January 2017

The authors conducted a clinical investigation on sixty-nine pregnant women, anaemic and non-anaemic, the purpose being to assess the effect of 50 days treatment with four different medicinal iron preparations, namely, ferrous sulphate, iron chondroitinsulfuric acid complex, and ferritin alone or associated with folinic acid and cobamamide, on various haematological parameters (Hb, RCC, Ht, CV, Iron, and Transferrin IBC). The four products demonstrated a similar efficacy in maintaining anaemic conditions under control; moreover, the results confirmed our hypothesis of the absorption of iron ferritin. While three products were well tolerated, ferrous sulphate induced, in some cases, side-effects.
A Double-Blind Controlled Subjective Study of a New Pharmaceutical Preparation of Lormetazepam versus Placebo in Patients with Chronic Sleep Disturbances
Authors: Meco G , Lestingi L , Barbieri M R , Bove R , Maltese A 
Published: January 2017

A double-blind crossover trial was carried out on the sleep-inducing activity of a new preparation (oral drops) of lormetazepam versus placebo. Twenty patients were included and requested to subjectively evaluate their sleep, both by analogue scales and semiquantitative ratings, during 2-night administration of the two products. Also, the usual parameters, sleep duration, sleep latency and number of awakenings were evaluated. Lormetazepam drops appeared to exert the same actions as the capsules' preparation, being significantly different from those of the placebo.
Evaluation of Reproterol's Effectiveness in Preventing Exercise-Induced Bronchospasm in Children
Authors: Verini M , Ansaloni A , Di Vincenzo M G , Napoleone M , Morgese G 
Published: January 2017

The authors have evaluated the effectiveness of the protection of a new beta2-adrenergic compound, reproterol, against broncho-constriction induced by physical exercise in a group of individuals of paediatric age sensitive to broncho-stimulation. This study has been carried out comparing reproterol with salbutamol, using placebo as a control, following a randomized single-blind crossover trial. The provocation test has been performed following the instructions of the Italian Society of Paediatrics. The drugs have been administered in the oral liquid form at the dose of 0·28 mg/kg and 0·1 mg/kg of reproterol and salbutamol, respectively. The two substances have shown a similar preventive effectiveness in controlling exercise-induced asthma up to 2 hours from administration with reproterol having a stronger action at the beginning of the observation.
The Role of Ketotifen in Children with Recurrent Bronchitis
Authors: Suwanjutha Subharee , Chantarojanasiri Teerachai 
Published: January 2017

The efficacy and safety of ketotifen in the treatment of recurrent bronchitis were studied in twenty Thai children with an average age of 5·3 years. Symptoms studied were cough, hypersecretion and wheezing and 4-point rating scores were assigned to each of the symptoms with regard to their frequency, severity and duration. Score per dose of the symptomatic agents used was also given. The symptoms and the use of symptomatic agents were recorded during a full year prior to ketotifen treatment and during a further full year study period. PEFR measurement was performed in the children above the age of 6 years at 2-weekly intervals under the supervision of the authors at the clinic. Assessment of efficacy was done by comparing monthly symptom scores and medication scores during the study period with the mean value of the previous year. Thirteen children received ketotifen for the whole year while seven children who were almost symptom-free after 4 months ketotifen treatment, were then only observed for a further 8 months. At the end of the study period, ketotifen treatment was rated very good and good in 85% of children, satisfactory in 10% and poor in 5%. Drowsiness was the only side-effect reported in a few cases but then only initially. There were no abnormalities in any laboratory parameters studied.
Piretanide, a Potassium Stable Diuretic, in the Treatment of Essential Hypertension: A Double-Blind Comparison of Two Formulations
Authors: Dols W , Verho M , Rangoonwala B , Jaeger S 
Published: January 2017

In a randomized double-blind parallel group study the effects of two formulations of piretanide (standard tablet and slow-release capsule) were compared in patients with mild to moderate essential hypertension. Forty patients entered the study and thirty-seven completed it. Both formulations of piretanide produced a significant reduction in erect and supine blood pressure which was evident at 2 weeks and was maintained and further enhanced over the ensuing trial period. A mean maximal fall in supine diastolic pressure of 22% was observed in the piretanide tablet group, and of 20% in the slow-release piretanide group. Blood pressure fell more quickly at the beginning of treatment with the tablet preparation, such that there was a significant difference between the groups up to the fourth week. After this point the blood pressure lowering effect was very similar in both groups and there was a progressive reduction in supine blood pressures over the 12-week active-treatment period. Slow-release piretanide produced a smoother effect than the tablet formulation. There were no significant changes in serum potassium and serum magnesium in either treatment group. Minor changes were seen in some other biochemical and haematological variables but these were of no clinical significance. Three patients were withdrawn from the study because of side-effects: one because of an excessive antihypertensive response to the tablet formulation; and two because of allergic reactions to the slow-release preparation. Side-effects were otherwise mild and infrequent.
The Effectiveness of Glycosaminoglycans in Peripheral Vascular Disease Therapy: A Clinical and Experimental Trial
Authors: Corsi C , Bocci L , Cipriani C , Gazzini A , Marrapodi E 
Published: January 2017

Thirty patients suffering from peripheral vascular disease (stage–II according to Fontaine) were included in a double-blind study aimed at assessing the efficacy of a high-dose glycosaminoglycan (GAG) (Sulodexide) both in terms of laboratory parameters, such as lipid metabolism and blood coagulation components, and instrumental procedures (strain-gauge plethysmography). Compared with the fifteen control patients (treated with placebo), the fifteen patients treated with Sulodexide showed a signficant decrease in blood triglycerides and fibrinogen as well as a significantly increased HDL-cholesterol, and positive instrumental changes: at the end of treatment Peak and Rest Flow values – and consequently also Winsor's index – were significantly increased only in patients treated with Sulodexide.
Ibuprofen: Plasma Concentrations in Man
Authors: Janssen G M E , Venema J F 
Published: January 2017

The plasma levels of Ibuprofen were measured in five healthy subjects who took 600 mg tablets of Ibuprofen twice daily, three times daily and four times daily in a crossover study. Peak plasma levels were obtained 1 hour after the first dose in all but one subject (slow absorber), the mean peak value being 51·3 μg.ml−1 (range 39·4–63·7 μg.ml−1). After the repeated dose regimens of two, three or four times daily of ibuprofen, the peak levels achieved were in a similar range to those seen after the first dose: Twice daily 39·4–66·4 μg.ml−1 Three times daily 43·6–63·3 μg.ml−1 Four times daily 44·1–58·4 μg.ml−1 There was no evidence of accumulation of the drug and no side-effects occurred during the trial.
A Double-Blind Comparison of Acebutolol (Sectral) and Propranolol (Inderal) in the Treatment of Hypertension in Black Nigerian Patients
Authors: Abengowe C U 
Published: January 2017

Acebutolol and propranolol were compared in forty-five Black African patients in a double-blind randomized trial carried out at Ahmadu Bello University Teaching Hospital in Kaduna, Nigeria. After a wash-out period of 6 weeks, including placebo administration for the last 4 of those weeks, twenty-seven patients were given acebutolol once daily and eighteen were given propranolol twice daily for 12 weeks, followed by a tapering-off period of 2 weeks, making a total of 14 weeks on active treatment. The two beta-receptor blocking drugs were effective in controlling hypertension with final daily doses ranging from 160 to 320 mg in the propranolol group and 400 to 800 mg in the acebutolol group. The supine systolic blood pressure responses with acebutolol were statistically significant and better than those elicited by propranolol. Acebutolol produced less (resting) bradycardia than did propranolol; this may be related to acebutolol's intrinsic sympathomimetic activity. The only unpleasant side effects reported in this study were slight dizziness in two patients treated with propranolol and slight tiredness in one patient treated with acebutolol. No significant abnormal changes were noted in laboratory tests or chest X-rays. Electrocardiography detected supraventricular tachyarrythmia in five patients: this disappeared by the end of the study. Acebutolol was shown to be a safe, effective and reliable antihypertensive drug, at least comparable to and probably slightly better than, propranolol in the treatment of hypertension in Black Nigerians. It has the added advantage of a once-daily dose schedule.
Intramuscular Piroxicam, a New Dosage Form, in the Treatment of Acute Musculoskeletal Disorders
Authors: Wiseman R L , Kilgour M 
Published: January 2017

Ten investigators in Austria, Belgium, Denmark, Germany and Switzerland participated in an open trial of intramuscular piroxicam involving 135 patients with selected acute sprains, tendinitis or low back pain. The drug was given in the recommended regimen of 40 mg once daily for 2 days and 20 mg once daily thereafter. Statistically significant improvement from baseline in pain was evident within 1 hour of the initial dose, an effect which was enhanced over a 12-hour period and which lasted for 24 hours. After 3 days of intramuscular injections, pain, tenderness, morning stiffness and back elongation were markedly improved. Subsequent treatment with either intramuscular or oral piroxicam further improved these symptoms and most patients recovered their normal physical activity within a week. The drug was well tolerated; twenty-five patients (18·5%) reported side-effects possibly related to piroxicam. Nearly all were mild or moderate in severity with only six resulting in disruption of therapy. Most adverse reactions involved the upper gastrointestinal tract, but there were no reports of gastric bleeding. Except for a few patients with injection site pain, the side-effect profile was similar to that established with the oral dosage form. Toleration was regarded as excellent or good in about 84% of the patients. The results indicate that intramuscular piroxicam can provide rapid and effective therapy with good toleration in the treatment of acute musculoskeletal disorders.
Lack of Effect of Ambroxol, a Bronchial Secretolytic Agent, on Gastric Mucus in Man
Authors: Guslandi M , Zanoni M E 
Published: January 2017

The effect of ambroxol, a bronchial mucolytic agent, on gastric mucus was investigated in man. Ten patients with bronchial hypersecretion were treated with ambroxol 30 mg t.i.d. by the oral route for 10 days. Before and after treatment the amount of total mucoproteins in the gastric juice was measured and a ‘mucoprotective index’ was calculated. Neither quantitative nor qualitative changes in gastric mucus were observed after ambroxol treatment. Our results show that the drug does not exert lytic effects on the gastric mucus layer and hence is devoid of damaging activity on the gastric mucosa.
Efficacy and Clinical Tolerance of a New Combination of Trimethoprim with Sulphonamide
Authors: Celotti Fabio , Nüdemberg Franklin , Magni Osvaldo , Piaia Francesca 
Published: January 2017

To obtain a direct clinical evaluation of a new sulpha-trimethoprim combination product (Kelfiprim®) from general practitioners or specialist practitioners, an extensive post-marketing survey has been organized in Brazil involving 1,177 doctors and 5,885 patients. These experienced different infections susceptible to oral antimicrobial chemotherapy with a sulpha-trimethoprim combination. The results indicated that the product was very effective (91.2% cure rate) and well tolerated (4% incidence of side-effects). Side-effects were usually mild and transient. No life-threatening adverse reactions were observed. The results obtained support those already published in clinical trials involving 1,119 patients.
Evaluation Clinique de la Flucloxacilline* dans le Traitement des Infections Staphylococciques Graves Chez l'Enfant
Authors: Saied H , Ben Attia Docteur M 
Published: January 2017

Vingt neuf malades au total ont été admis dans le service de pédiatrie avec une infection staphylococcique confirmée ou presumée; ils ont ensuite été traités par un antibiotique à spectre étroit – la flucloxacilline. En dépit de la gravité de leur condition, une guerison a été observée chez tous les malades sauf deux. Il n'a pas été observé d'effets secondaires associés au traitement. A total of twenty-nine children were admitted to the paediatric unit with confirmed or presumed staphylococcal infection and subsequently treated with the narrow spectrum antibiotic – flucloxacillin. Despite the gravity of their condition all but two patients made a satisfactory recovery. There were no side-effects associated with this treatment.
Uncomplicated Urinary Tract Infections: Lomefloxacin versus Trimethoprim/Sulphamethoxazole
Authors: Guibert J , Capron M H 
Published: January 2017

Data were collected from 14 French centres which participated in a randomized study to compare the safety and efficacy of 400 mg lomefloxacin taken orally once daily by 62 patients with 160/800 mg trimethoprim/sulphamethoxazole (TMP/SMX) taken orally twice daily by 64 patients with uncomplicated urinary tract infections. Most patients were infected with Escherichia coli at baseline (72.4% in the lomefloxacin group and 69.0% in the TMP/SMX group) and all patients were treated for 5 days. At 5 − 9 days post-treatment, lomefloxacin had eradicated the causative organism of infection in 100% of evaluable patients treated with lomefloxacin compared with 86.7% of those treated with TMP/SMX. At 4 − 6 weeks post-treatment, there were no marked differences in eradication rates between the two treatment groups: 83.3% and 80.0% for the lomefloxacin and TMP/SMX groups, respectively. Clinical cure rates showed no marked differences between treatment groups at 5 − 9 days or at 4 − 6 weeks post-treatment. At 5 − 9 days post-treatment, lomefloxacin achieved a clinical cure rate of 78.6% compared with 86.7% for TMP/SMX evaluable patients. At 4 − 6 weeks post-treatment, the clinical cure rates were 66.7% and 86.7% for the evaluable lomefloxacin- and TMP/SMX-treated patients, respectively. Both treatment regimens were well tolerated with a low incidence of adverse events. In conclusion, once-daily oral dosing with lomefloxacin is a safe and efficacious alternative to twice-daily dosing with TMP/SMX in the treatment of uncomplicated urinary tract infections.